Q1 EPS Estimate for Y-mAbs Therapeutics Reduced by Analyst
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) – Equities researchers at Brookline Capital Management reduced their Q1 2025 EPS estimates for shares of Y-mAbs Therapeutics in a research report issued on Tuesday, April 22nd. Brookline Capital Management analyst K. Dolliver now anticipates that the company will earn ($0.22) per share for the quarter, down from […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) – Equities researchers at Brookline Capital Management reduced their Q1 2025 EPS estimates for shares of Y-mAbs Therapeutics in a research report issued on Tuesday, April 22nd. Brookline Capital Management analyst K. Dolliver now anticipates that the company will earn ($0.22) per share for the quarter, down from […]
